Halozyme Therapeutics Presents Pre-Clinical Studies On Dermal Remodeling With HTI-501, A Lysosomal Proteinase

Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix (”Matrix”), announced the presentation of new pre-clinical findings on the controlled modification of the Matrix with HTI-501 at the European Society for Dermatological Research (ESDR) and Japanese Society for Investigative Dermatology (JSID).

More: continued here

Filed under: Dermatology on May 22nd, 2008